Generative AI is continuing to reshape drug discovery as biotechnology companies use machine learning to shorten development timelines and identify novel therapeutic targets. Insilico Medicine has announced the nomination of ISM9077 as its latest preclinical candidate, an AI-designed small-molecule therapy aimed at treating multiple inflammatory eye diseases while also supporting broader research into aging and chronic inflammatory disorders.
Artificial intelligence is increasingly influencing how new medicines are discovered, enabling biotechnology companies to design novel drug candidates faster than conventional research approaches. Clinical-stage biotech company Insilico Medicine has announced the nomination of ISM9077 as a Preclinical Candidate (PCC), expanding its portfolio of AI-designed therapeutics targeting ophthalmology and age-related diseases.
The announcement marks the 32nd preclinical candidate nominated by the company since 2021 and highlights the growing role of generative AI in accelerating early-stage pharmaceutical research. Developed using Insilico’s proprietary AI-driven drug discovery platform, ISM9077 is being investigated as a potential treatment for dry age-related macular degeneration (dry AMD), uveitis, and dry eye disease—three conditions with significant unmet clinical needs.
Unlike conventional drug discovery programs that often require years of medicinal chemistry optimization, ISM9077 was designed using Chemistry42, Insilico’s generative chemistry platform. The system applies structure-based drug design (SBDD) techniques alongside AI models to generate and optimize novel molecular structures based on target biology, pharmacological properties, and predicted drug-likeness.
According to the company, ISM9077 targets a previously underexplored biological pathway referred to as Target Y, combining a novel mechanism of action with the potential for both oral and topical eye-drop formulations. Preclinical studies suggest the compound demonstrates strong target inhibition across multiple species, favorable retinal exposure, good tissue permeability, and an encouraging safety profile.
One of the distinguishing aspects of the program is its potential to address multiple diseases using a single molecular mechanism. Beyond ophthalmology, Target Y has been associated with biological pathways involved in aging, chronic inflammation, and longevity. As a result, Insilico believes the candidate could eventually support research across broader therapeutic areas including neurodegenerative diseases, Inflammatory Bowel Disease (IBD), Metabolic Dysfunction-Associated Steatohepatitis (MASH), cardiovascular diseases, and obesity.
The announcement also reflects a growing trend in AI-powered drug development, where researchers seek to identify therapeutic targets with applications across multiple disease indications rather than focusing on a single condition. Such “pipeline-in-a-drug” strategies have become increasingly attractive because they may improve research efficiency while expanding commercial opportunities if clinical studies prove successful.
According to Insilico, AI played a central role throughout the discovery process. After generating structural insights from in-house crystallographic data, researchers used Chemistry42 to design entirely new molecular candidates optimized for pharmacophore fit, three-dimensional structure, and novelty. A target-specific AI prediction model was then used to rank generated compounds, allowing researchers to prioritize promising candidates for laboratory validation while reducing the number of molecules requiring synthesis.
The company reports that ISM9077 demonstrated encouraging results across several preclinical models. In dry AMD studies, the candidate improved retinal structure and visual function while outperforming currently available therapies on selected experimental endpoints. Independent studies in uveitis and dry eye disease also indicated reductions in ocular inflammation, improved retinal function, increased tear production, and faster therapeutic response compared with Cyclosporine A, a widely used treatment for dry eye disease.
While these findings remain limited to preclinical research, they support further evaluation before potential human clinical trials.
The ophthalmology market represents a significant commercial opportunity. According to industry research cited by the company, the global ocular disease therapeutics market exceeded US$40 billion in 2025 and is projected to approach US$72 billion by 2034, driven by aging populations and rising incidence of chronic eye diseases. Conditions such as dry AMD remain among the leading causes of irreversible vision loss in older adults, while inflammatory disorders including uveitis continue to have limited treatment options.
Beyond the individual drug candidate, Insilico also highlighted continued development of its broader AI platform. The company says it has reduced the average timeline for nominating preclinical candidates to 12–18 months, compared with the 2.5 to 4 years typically associated with traditional early-stage drug discovery. Since 2021, it has nominated 32 preclinical candidates, with 13 programs receiving Investigational New Drug (IND) approval or clearance.
Insilico is also expanding MMAI Gym, its AI benchmarking and model training platform designed to improve scientific reasoning capabilities for pharmaceutical AI systems. The platform enables organizations to train and evaluate AI models using domain-specific scientific tasks, with collaborators including Human Longevity and Liquid AI already participating.
The latest announcement underscores how AI is evolving from a research support tool into a core engine for pharmaceutical innovation. As biotechnology companies increasingly integrate generative AI, structural biology, and laboratory automation, success will ultimately depend on whether AI-designed molecules can consistently demonstrate safety and efficacy through clinical development. For now, ISM9077 represents another milestone in the industry’s effort to accelerate drug discovery through AI-native research platforms.
Market Landscape
AI-driven drug discovery has become one of the fastest-growing segments of the biotechnology industry. According to McKinsey & Company, generative AI could create $60–110 billion in annual value across pharmaceuticals by accelerating target identification, molecule design, and clinical development. Grand View Research projects sustained growth in the AI drug discovery market as pharmaceutical companies adopt machine learning, automation, and computational biology to improve R&D productivity.
Ophthalmology is also emerging as a key innovation area, driven by aging populations and increasing demand for therapies targeting retinal degeneration, inflammatory eye diseases, and chronic vision disorders.
Top Insights
- Insilico Medicine has nominated ISM9077 as its 32nd AI-designed preclinical drug candidate, targeting inflammatory eye diseases through a novel biological mechanism.
- The candidate was developed using the company’s Chemistry42 generative AI platform, combining structure-based drug design with AI-driven molecular optimization.
- Preclinical studies indicate encouraging efficacy across dry AMD, uveitis, and dry eye disease, with both oral and topical eye-drop delivery showing therapeutic potential.
- Target Y may support future research beyond ophthalmology, including aging, neurodegenerative disorders, inflammatory diseases, cardiovascular conditions, MASH, and obesity.
- The announcement highlights continued momentum in AI-powered drug discovery, where generative AI is shortening early-stage R&D timelines while enabling novel therapeutic design.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
